# OnCo record zanidatamab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/zanidatamab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "zanidatamab" ;
  schema:name "Zanidatamab"@en ;
  schema:description "Zanidatamab (Ziihera) is an antibody that grabs HER2 at two different spots, approved for HER2+ bile duct cancer."@en ;
  schema:url <https://onco.cc/drugs/zanidatamab/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Zanidatamab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q131405202> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Zanidatamab> ;
  onco:status "approved" ;
  onco:modality "Biparatopic bispecific antibody (HER2)" ;
  schema:alternateName "Ziihera" ;
  onco:approval "US 2024: HER2+ (IHC 3+) unresectable/metastatic biliary tract cancer, previously treated", "EU 2025: HER2+ biliary tract after ≥1 line; 27 Jun 2025 (conditional)", "UK 2026: HER2-positive (IHC 3+) unresectable locally advanced or metastatic biliary tract cancer after at least one line of systemic treatment; MHRA 19 February 2026, NICE TA1153 published 7 May 2026 with a commercial arrangement" ;
  onco:acceleratedApproval "US 2024-11-20: Treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test" ;
  onco:related <https://onco.cc/biomarkers/her2-ihc-3-plus/> ;
  onco:cancers <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/gallbladder/>, <https://onco.cc/cancers/biliary-tract-cancer/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:companies <https://onco.cc/companies/jazz/>, <https://onco.cc/companies/zymeworks/>, <https://onco.cc/companies/beone/> ;
  onco:terms <https://onco.cc/terms/her2-testing-in-biliary-cancer/> ;
  onco:trials <https://onco.cc/trials/nct06435429/>, <https://onco.cc/trials/nct07102381/>, <https://onco.cc/trials/nct06695845/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-harding-lancet-oncol/>, <https://onco.cc/key-papers/paper-angerilli-her2-ihc-cish-biliary-hum-pathol-2026/> .